pharmaphorum

AUGUST 10, 2021

The three-year project – led by respiratory medicine expert Dr Timothy Hinks from the Oxford University Respiratory Medicine Unit – will use whole-genome sequencing of around 500 patients with severe asthma, comparing their gene sequences with control subjects who don’t have asthma.

Gene Sequencing 116

Gene Sequencing Gene Bioinformatics Genome 116

pharmaphorum

OCTOBER 12, 2022

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. The deal focuses on mRNA-4157 – also known as V940 – which targets up to 34 unique tumour-associated antigens or neoantigens that are expressed by a patient’s cancer cells.

Vaccination 105

Vaccination Vaccine Gene Sequencing RNA 105

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

Roots Analysis

FEBRUARY 23, 2022

Over the past few years, several companies have started offering a diverse range of genome sequencing products and services using various second and third generation sequencing technologies. Next Generation Sequencing (NGS) Library Preparation Kits. Next Generation Sequencing (NGS) Library Preparation Kits.

Genetics 52

Genetics DNA RNA Reagent 52

pharmaphorum

DECEMBER 14, 2022

The two partners have revealed the first clinical data from a phase 2b trial of a personalised vaccine consisting of 34 mRNAs, each targeting mutations – identified by gene sequencing – that are thought to be driving a patient’s cancer. Access to sequencing could, however, be a major obstacle at the population level.

Vaccination 98

Vaccination Vaccine Trials Gene Sequencing 98

FDA Law Blog

OCTOBER 24, 2024

Gibbs — A recent blog post focused on the potentially negative implications of the proposed Patent Eligibility Restoration Act (PERA) for manufacturers of generic drugs and biosimilar products. Courts have interpreted the statutory categories to exclude, inter alia , natural phenomena, including products of nature.

Gene 64

Gene DNA Genetics Gene Sequencing 64